Novartis Plans $23 Bn US Expansion With New Morrisville Manufacturing Facility

The facility is part of the company’s broader $23 billion investment commitment in US-based manufacturing, research, and development.

Basel-based pharmaceutical company Novartis has announced plans to establish a new manufacturing facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient (API) production for solid dosage tablets, capsules, and RNA therapeutics. The facility is part of the company’s broader $23 billion investment commitment in US-based manufacturing, research, and development.

The 56,200-square-foot facility is designed to strengthen end-to-end production capabilities in the United States, covering processes from active ingredients to finished medicines. It will also support the development and supply of future therapies, including advanced treatment platforms.

Novartis said the new site marks its seventh planned facility within a year of announcing its large-scale US expansion strategy. Once operational, the facility will increase the company’s presence in North Carolina to five facilities across three locations.

According to the company, the investment is intended to improve local development and production capacity while ensuring faster access to medicines for patients in the US. The expansion also supports manufacturing for complex therapies, including RNA-based treatments and radioligand therapies (RLTs), which are used in cancer care.

“Last year we committed to adding seven new facilities in the US, and today we finalize our plans to expand our US manufacturing and R&D footprint in the US,” said Vas Narasimhan, CEO of Novartis. He added that building an integrated manufacturing network will help accelerate the development and delivery of medicines at scale.

Since April 2025, Novartis has advanced multiple projects under its US investment plan. These include a biomedical research center in San Diego, a manufacturing facility in Denton, Texas, for cancer-focused RLTs, and a new RLT site in Winter Park, Florida. The company has also expanded operations in California, Indiana, and New Jersey, alongside a flagship manufacturing hub under development in North Carolina.

The company stated it is moving toward establishing end-to-end US manufacturing for all major technology platforms, including small molecules, biologics, RNA therapies, and cell and gene therapies.

Stay tuned for more such updates on Digital Health News